Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

ACADIA Pharmaceuticals stock price, quote, forecast and news

ACAD
US0042251084
603035

Price

16.07
Today +/-
-0.14
Today %
-0.93 %
P

ACADIA Pharmaceuticals stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the ACADIA Pharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the ACADIA Pharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the ACADIA Pharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze ACADIA Pharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

ACADIA Pharmaceuticals Stock Price History

DateACADIA Pharmaceuticals Price
9/6/202416.07 undefined
9/5/202416.22 undefined
9/4/202416.69 undefined
9/3/202416.36 undefined
8/30/202416.58 undefined
8/29/202416.32 undefined
8/28/202415.70 undefined
8/27/202415.75 undefined
8/26/202416.09 undefined
8/23/202415.94 undefined
8/22/202415.68 undefined
8/21/202415.93 undefined
8/20/202415.57 undefined
8/19/202415.76 undefined
8/16/202415.40 undefined
8/15/202415.40 undefined
8/14/202415.14 undefined
8/13/202415.73 undefined
8/12/202415.29 undefined

ACADIA Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into ACADIA Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by ACADIA Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects ACADIA Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of ACADIA Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into ACADIA Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing ACADIA Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on ACADIA Pharmaceuticals’s growth potential.

ACADIA Pharmaceuticals Revenue, EBIT and net profit per share

DateACADIA Pharmaceuticals RevenueACADIA Pharmaceuticals EBITACADIA Pharmaceuticals Net Income
2029e1.5 B undefined0 undefined339.53 M undefined
2028e1.52 B undefined555.99 M undefined452.05 M undefined
2027e1.38 B undefined462.93 M undefined374.49 M undefined
2026e1.2 B undefined289.5 M undefined207.7 M undefined
2025e1.08 B undefined181.16 M undefined140.62 M undefined
2024e971.16 M undefined88.2 M undefined88.15 M undefined
2023726.44 M undefined-73.38 M undefined-61.29 M undefined
2022517.2 M undefined-223.6 M undefined-216 M undefined
2021484.1 M undefined-170.4 M undefined-167.9 M undefined
2020441.8 M undefined-286.6 M undefined-281.6 M undefined
2019339.1 M undefined-246.5 M undefined-235.3 M undefined
2018223.8 M undefined-247.4 M undefined-245.2 M undefined
2017124.9 M undefined-292.4 M undefined-289.4 M undefined
201617.3 M undefined-272.8 M undefined-271.4 M undefined
2015100,000 undefined-164.6 M undefined-164.4 M undefined
2014100,000 undefined-93.2 M undefined-92.5 M undefined
20131.1 M undefined-38.3 M undefined-37.9 M undefined
20124.9 M undefined-20.9 M undefined-20.8 M undefined
20112.1 M undefined-21.2 M undefined-22.8 M undefined
201042.1 M undefined15.1 M undefined15.1 M undefined
20096.4 M undefined-44.2 M undefined-45.1 M undefined
20081.6 M undefined-64.8 M undefined-64.2 M undefined
20077.6 M undefined-62.7 M undefined-56.4 M undefined
20068.1 M undefined-52.7 M undefined-45 M undefined
200511 M undefined-29.6 M undefined-34.1 M undefined
20044.6 M undefined-26.1 M undefined-17.3 M undefined

ACADIA Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
00000000.010.0100.010.010.0100.010.04000000.020.120.220.340.440.480.520.730.971.081.21.381.521.5
----100.00100.00-25.00100.0016.67-42.86175.00-27.27-12.50-85.71500.00600.00-95.24100.00-75.00---629.4179.8452.0230.099.756.8240.4333.7511.4311.2814.8710.20-1.31
---------------------70.5989.5291.9394.1095.4696.2898.0794.21------
00000000000000000000-212111205319421466507684000000
00-3-6-7-11-15-12-13-26-29-52-62-64-4415-21-20-38-93-164-272-292-247-246-286-170-223-73881812894625550
----600.00-350.00-275.00-500.00-200.00-185.71-650.00-263.64-650.00-885.71-6,400.00-733.3335.71-1,050.00-500.00-3,800.00---1,600.00-235.48-110.76-72.57-64.85-35.12-43.13-10.069.0616.7324.0033.4136.42-
00-3-6-2-2-3-3-1-17-34-45-56-64-4515-22-20-37-92-164-271-289-245-235-281-167-216-6188140207374452339
---100.00-66.67-50.00--66.671,600.00100.0032.3524.4414.29-29.69-133.33-246.67-9.0985.00148.6578.2665.246.64-15.22-4.0819.57-40.5729.34-71.76-244.2659.0947.8680.6820.86-25.00
1.51.51.722.83.84.31.51.510.42227.935.237.137.538.752.255.185.797.2100.6115.9122.6126.6147.2157.3160.5161.7163.82000000
-----------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The ACADIA Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the ACADIA Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
199819992002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                               
17.612.212.427.235.94383.3126.960.147.137.131108185.8322.5215.1529341.3473.5697.4632520.7416.8438.87
0.20000000000000005.917.326.135.848.264.462.298.27
00000000000000001.21.11.72.12.10.90.94.08
00000000000000004.25.24.16.39.77.96.635.82
0.60.40.81.11.917.12.54.42.31.40.80.90.61.81.22.27.58.520.718.625.723.921.439.09
18.412.613.228.337.860.185.8131.362.448.537.931.9108.6187.6323.7217.3547.8373.4526.1760.2717.7617.8507.9616.13
2.32.52.43.12.52.33.532.11.10.40.200.60.62.23.12.73.312.756.466.361.656.47
000000000000000000000000
000000000000000000000000
000000000000000075.54.12.61.10065.49
000000000000000000000000
0.40.40.40.300.10.30.30.20.10.1000.20.30.73.22.86.77.67.41618.310.87
2.72.92.83.42.52.43.83.32.31.20.50.200.80.92.913.31114.122.964.982.379.9132.83
21.115.51631.740.362.589.6134.664.749.738.432.1108.6188.4324.6220.2561.1384.4540.2783.1782.6700.1587.8748.96
                                               
24.724.746.574.500000000000000000000.02
000.020.020.130.170.240.340.350.350.350.370.450.590.810.861.451.561.952.42.612.692.772.86
-9.4-16.8-54.3-68.4-94.3-128.4-173.5-229.9-294.1-339.2-324.1-346.9-367.7-405.7-498.1-662.6-934-1,223.7-1,468.9-1,704.1-1,985.7-2,153.6-2,369.6-2,430.84
-200-300-900-2,500-1,800-60020050030050050000000100-400-4003000-200-1,00024
000000000000000000000000
16.39.36.321.830.739.467.1113.95312.229.723.385182309.5199.7518.4335.2479699.1627540.8400.3431.76
0.30.21.11.52.22.13.42.62.32.9221.40.421.73.98.83.27.28.56.912.717.54
0.80.71.72.13.715.313.5157.55.43.23.54.16.613.820.23640.256.467.697.589.2112.9236.71
0.30.30.31.31.33.42.70.70.460.70.70.40.1002.60000000
000000000000000000000000
0.10.633.21.50.9110.80.40.10000000000000
1.51.86.18.18.721.720.619.31114.766.25.97.115.821.942.54959.674.810696.1125.6254.25
3.44.43.51.610.91.41.20.40.100000000000000
000000000000000000000000
000000.50.50.20.222.82.72.617.700.10.20.20.21.69.249.663.261.862.95
3.44.43.51.611.41.91.40.622.92.72.617.700.10.20.20.21.69.249.663.261.862.95
4.96.29.69.79.723.122.520.711.637.68.78.823.67.115.922.142.749.261.284155.6159.3187.4317.2
21.215.515.931.540.462.589.6134.664.649.838.432.1108.6189.1325.4221.8561.1384.4540.2783.1782.6700.1587.7748.96
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of ACADIA Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand ACADIA Pharmaceuticals's financial health and stability.

Assets

ACADIA Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that ACADIA Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of ACADIA Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into ACADIA Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
19971998199920012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
-2-6-7-14-12-14-25-34-45-56-64-4515-22-20-37-92-164-271-289-245-235-281-167-215-61
00011111011100000012322325
00000000000000000000000000
0000111110-3-527-270-2-1946-6-8311-243718
000211212364243123278110150164159215127130120
00000000000000000000000000
00000000000000000001111125
-2-5-5-11-9-9-20-20-41-54-64-13-10-19-21-31-66-121-208-217-167-151-136-125-11416
-1-1-100-10-1-200000000-2-90-2-1-7-10-40
-1-14383-14-7-19-22-41699-15-25-126-87147-26192-71-165192-717331
0-12494-12-6-18-20-41699-15-25-125-87149-25293-69-164200-697372
00000000000000000000000000
12114-1-10000000000000000000
15100002831416998010149811120314518313063718118825
17121142630407098010139811120314533313063718118825
000000000000000000140000000
00000000000000000000000000
12-7-1-1-1121514-3-11051-46504063-946754137-178-3273
-4.43-7.15-7.12-12.24-9.62-11.6-21.28-21.28-43.45-55.35-65.1-13.77-10.7-19.9-21.63-32.39-66.61-123.94-217.92-218.57-169.62-152.26-143.76-126.78-114.04-23.35
00000000000000000000000000

ACADIA Pharmaceuticals stock margins

The ACADIA Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of ACADIA Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for ACADIA Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the ACADIA Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the ACADIA Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the ACADIA Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the ACADIA Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the ACADIA Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the ACADIA Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the ACADIA Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

ACADIA Pharmaceuticals Margin History

ACADIA Pharmaceuticals Gross marginACADIA Pharmaceuticals Profit marginACADIA Pharmaceuticals EBIT marginACADIA Pharmaceuticals Profit margin
2029e94.27 %0 %22.56 %
2028e94.27 %36.48 %29.66 %
2027e94.27 %33.47 %27.08 %
2026e94.27 %24.04 %17.25 %
2025e94.27 %16.74 %13 %
2024e94.27 %9.08 %9.08 %
202394.27 %-10.1 %-8.44 %
202298.05 %-43.23 %-41.76 %
202196.28 %-35.2 %-34.68 %
202095.34 %-64.87 %-63.74 %
201994.22 %-72.69 %-69.39 %
201891.82 %-110.55 %-109.56 %
201789.51 %-234.11 %-231.71 %
201674.57 %-1,576.88 %-1,568.79 %
2015-2,400 %-164,600 %-164,399.99 %
2014100 %-93,199.99 %-92,500 %
201394.27 %-3,481.82 %-3,445.45 %
201294.27 %-426.53 %-424.49 %
201194.27 %-1,009.52 %-1,085.71 %
201094.27 %35.87 %35.87 %
200994.27 %-690.63 %-704.69 %
200894.27 %-4,050 %-4,012.5 %
200794.27 %-825 %-742.11 %
200694.27 %-650.62 %-555.56 %
200594.27 %-269.09 %-310 %
200494.27 %-567.39 %-376.09 %

ACADIA Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The ACADIA Pharmaceuticals earnings per share therefore indicates how much revenue ACADIA Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue ACADIA Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates ACADIA Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of ACADIA Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating ACADIA Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

ACADIA Pharmaceuticals Revenue, EBIT and net profit per share

DateACADIA Pharmaceuticals Sales per ShareACADIA Pharmaceuticals EBIT per shareACADIA Pharmaceuticals Earnings per Share
2029e9.07 undefined0 undefined2.05 undefined
2028e9.19 undefined0 undefined2.73 undefined
2027e8.34 undefined0 undefined2.26 undefined
2026e7.26 undefined0 undefined1.25 undefined
2025e6.52 undefined0 undefined0.85 undefined
2024e5.85 undefined0 undefined0.53 undefined
20234.43 undefined-0.45 undefined-0.37 undefined
20223.2 undefined-1.38 undefined-1.34 undefined
20213.02 undefined-1.06 undefined-1.05 undefined
20202.81 undefined-1.82 undefined-1.79 undefined
20192.3 undefined-1.67 undefined-1.6 undefined
20181.77 undefined-1.95 undefined-1.94 undefined
20171.02 undefined-2.38 undefined-2.36 undefined
20160.15 undefined-2.35 undefined-2.34 undefined
20150 undefined-1.64 undefined-1.63 undefined
20140 undefined-0.96 undefined-0.95 undefined
20130.01 undefined-0.45 undefined-0.44 undefined
20120.09 undefined-0.38 undefined-0.38 undefined
20110.04 undefined-0.41 undefined-0.44 undefined
20101.09 undefined0.39 undefined0.39 undefined
20090.17 undefined-1.18 undefined-1.2 undefined
20080.04 undefined-1.75 undefined-1.73 undefined
20070.22 undefined-1.78 undefined-1.6 undefined
20060.29 undefined-1.89 undefined-1.61 undefined
20050.5 undefined-1.35 undefined-1.55 undefined
20040.44 undefined-2.51 undefined-1.66 undefined

ACADIA Pharmaceuticals business model

ACADIA Pharmaceuticals Inc is a biopharmaceutical company based in San Diego, California. The company was founded in 1993 and specializes in the development and commercialization of medications for neurological disorders. ACADIA Pharmaceuticals is one of the most popular companies on Eulerpool.com.

ACADIA Pharmaceuticals SWOT Analysis

Strengths

ACADIA Pharmaceuticals Inc. has several strengths that contribute to its success:

  • Strong portfolio of innovative and effective drugs
  • Solid financial performance and revenue growth
  • Robust research and development capabilities
  • Strong brand reputation and recognition
  • Strong relationships with healthcare providers and pharmaceutical partners

Weaknesses

ACADIA Pharmaceuticals Inc. also has some weaknesses that it needs to address:

  • Reliance on a limited number of product offerings
  • High production and marketing costs
  • Limited geographical presence and market reach
  • Dependency on regulatory approvals

Opportunities

ACADIA Pharmaceuticals Inc. can capitalize on the following opportunities:

  • Growing demand for neurological and psychiatric treatments
  • Expansion into new markets and regions
  • Investment in research and development to develop new drugs
  • Strategic partnerships and collaborations for market growth

Threats

ACADIA Pharmaceuticals Inc. should remain vigilant about potential threats:

  • Intense competition from other pharmaceutical companies
  • Stringent regulatory requirements and approval processes
  • Challenges in intellectual property protection
  • Economic and political uncertainties impacting the healthcare industry

ACADIA Pharmaceuticals Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

ACADIA Pharmaceuticals historical P/E ratio, EBIT, and P/S ratio.

ACADIA Pharmaceuticals shares outstanding

The number of shares was ACADIA Pharmaceuticals in 2023 — This indicates how many shares 163.819 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue ACADIA Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates ACADIA Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of ACADIA Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating ACADIA Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for ACADIA Pharmaceuticals.

ACADIA Pharmaceuticals latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20240.18 0.2  (9.83 %)2024 Q2
3/31/20240.05 0.1  (109.64 %)2024 Q1
12/31/20230.31 0.28  (-9.65 %)2023 Q4
9/30/2023-0.43 -0.4  (7.96 %)2023 Q3
6/30/2023-0.08 0.01  (111.86 %)2023 Q2
3/31/2023-0.22 -0.27  (-23.29 %)2023 Q1
12/31/2022-0.25 -0.26  (-4.92 %)2022 Q4
9/30/2022-0.19 -0.17  (12.05 %)2022 Q3
6/30/2022-0.25 -0.21  (16.86 %)2022 Q2
3/31/2022-0.61 -0.33  (46.18 %)2022 Q1
1
2
3
4
5
...
9

Eulerpool ESG Scorecard© for the ACADIA Pharmaceuticals stock

Eulerpool World ESG Rating (EESG©)

54/ 100

🌱 Environment

20

👫 Social

99

🏛️ Governance

42

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

ACADIA Pharmaceuticals list of shareholders

%
Name
Stocks
Change
Date
8.06268 % The Vanguard Group, Inc.13,374,376-220,73112/31/2023
6.78415 % RTW Investments L.P.11,253,551-322,98612/31/2023
5.74221 % BlackRock Institutional Trust Company, N.A.9,525,170914,75812/31/2023
3.89741 % State Street Global Advisors (US)6,465,0261,251,29512/31/2023
3.61194 % EcoR1 Capital, LLC5,991,479012/31/2023
3.17420 % Fidelity Management & Research Company LLC5,265,358-36,62212/31/2023
3.01234 % T. Rowe Price Associates, Inc.4,996,868-47,01012/31/2023
25.84074 % Baker Bros. Advisors LP42,864,612012/31/2023
2.26344 % D. E. Shaw & Co., L.P.3,754,598-1,034,40012/31/2023
1.91510 % Fred Alger Management, LLC3,176,77567,89212/31/2023
1
2
3
4
5
...
10

ACADIA Pharmaceuticals Executives and Management Board

Mr. Stephen Davis62
ACADIA Pharmaceuticals Chief Executive Officer, Director (since 2014)
Compensation 14.03 M
Mr. Mark Schneyer49
ACADIA Pharmaceuticals Chief Financial Officer, Executive Vice President
Compensation 2.35 M
Mr. Brendan Teehan54
ACADIA Pharmaceuticals Chief Operating Officer, Executive Vice President, Head of Commercial
Compensation 2.3 M
Dr. Stephen Biggar52
ACADIA Pharmaceuticals Independent Chairman of the Board
Compensation 427,343
Ms. Laura Brege64
ACADIA Pharmaceuticals Independent Director
Compensation 387,343
1
2
3

ACADIA Pharmaceuticals Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Neuren Pharmaceuticals Stock
Neuren Pharmaceuticals
SupplierCustomer0,710,610,810,350,40-0,48
Stoke Therap Stock
Stoke Therap
SupplierCustomer0,600,520,950,790,130,70
Siegfried Holding Stock
Siegfried Holding
SupplierCustomer0,260,810,880,49-0,12-0,73
Ipsen Stock
Ipsen
SupplierCustomer0,010,840,670,130,38-0,49
Thermo Fisher Scientific Stock
Thermo Fisher Scientific
SupplierCustomer-0,470,380,620,31-0,05-0,62
1

Most common questions regarding ACADIA Pharmaceuticals

What values and corporate philosophy does ACADIA Pharmaceuticals represent?

ACADIA Pharmaceuticals Inc represents values of innovation, excellence, and compassion in the pharmaceutical industry. The company's corporate philosophy revolves around developing breakthrough therapies that address unmet medical needs, with a particular focus on neurological and central nervous system disorders. ACADIA Pharmaceuticals Inc aims to improve patients' lives by delivering novel treatments and advancing scientific understanding. With a commitment to rigorous research, collaboration, and patient-centricity, the company strives to make a meaningful impact in healthcare. ACADIA Pharmaceuticals Inc embraces a culture of continuous learning, growth, and ethical practices to drive positive change and bring hope to those in need.

In which countries and regions is ACADIA Pharmaceuticals primarily present?

ACADIA Pharmaceuticals Inc is primarily present in the United States.

What significant milestones has the company ACADIA Pharmaceuticals achieved?

ACADIA Pharmaceuticals Inc has achieved several significant milestones. The company's groundbreaking drug, pimavanserin, received FDA approval in 2016 for the treatment of Parkinson's disease psychosis (PDP). This made ACADIA the first and only pharmaceutical company with an FDA-approved treatment for this condition. In 2020, ACADIA also received FDA approval for pimavanserin as a treatment for hallucinations and delusions associated with dementia-related psychosis (DRP). These approvals have not only established ACADIA as a leader in the field of neurological therapeutics but also provided hope and improved quality of life for patients suffering from debilitating psychotic symptoms.

What is the history and background of the company ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company that specializes in the development and commercialization of innovative medicines to address unmet medical needs. Founded in 1997, ACADIA has been dedicated to advancing breakthrough therapies for central nervous system disorders. The company focuses on researching and developing small molecule drugs that target specific neurotransmitter receptors in the brain. ACADIA is recognized for its leading drug, Nuplazid, which is approved for the treatment of Parkinson's disease psychosis. Committed to improving patients' lives, ACADIA strives to drive scientific advancements and create value for healthcare providers and stakeholders in the pharmaceutical industry.

Who are the main competitors of ACADIA Pharmaceuticals in the market?

The main competitors of ACADIA Pharmaceuticals Inc in the market are Biogen Inc., AbbVie Inc., and Johnson & Johnson.

In which industries is ACADIA Pharmaceuticals primarily active?

ACADIA Pharmaceuticals Inc is primarily active in the biopharmaceutical industry.

What is the business model of ACADIA Pharmaceuticals?

The business model of ACADIA Pharmaceuticals Inc revolves around the research, development, and commercialization of innovative therapies for central nervous system disorders. With a focus on neurology and psychiatry, ACADIA develops and markets drugs that aim to improve the lives of patients suffering from neurological and psychiatric conditions such as Parkinson's disease, schizophrenia, and Alzheimer's disease. Through strategic collaborations, clinical trials, and regulatory approvals, ACADIA aims to bring transformative therapies to market, addressing unmet medical needs in the field of central nervous system disorders. ACADIA Pharmaceuticals Inc continuously strives to enhance patient outcomes and maximize shareholder value through its dedicated efforts in drug development and commercialization.

What is the P/E ratio of ACADIA Pharmaceuticals 2024?

The ACADIA Pharmaceuticals P/E ratio is 29.86.

What is the P/S ratio of ACADIA Pharmaceuticals 2024?

The ACADIA Pharmaceuticals P/S ratio is 2.71.

What is the AlleAktien quality score of ACADIA Pharmaceuticals?

The AlleAktien quality score for ACADIA Pharmaceuticals is 6/10.

What is the revenue of ACADIA Pharmaceuticals 2024?

The expected ACADIA Pharmaceuticals revenue is 971.16 M USD.

How high is the profit of ACADIA Pharmaceuticals 2024?

The expected ACADIA Pharmaceuticals profit is 88.15 M USD.

What is the business model of ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for central nervous system (CNS) disorders. The company is headquartered in San Diego, California, USA. ACADIA Pharmaceuticals is divided into two divisions: clinical development and commercial marketing. In clinical development, the company is working on developing new drugs for the treatment of CNS disorders such as Parkinson's disease, Alzheimer's disease, depressive disorders, and schizophrenia. The goal is to help patients reduce their symptoms and improve their quality of life. The commercial division is responsible for bringing to market and distributing the medication developed by ACADIA Pharmaceuticals. In 2020, the company successfully entered the market with the medication Nuplazid, which is used to treat hallucinations and delusions in patients with Parkinson's disease. ACADIA Pharmaceuticals' business model is based on the development of drugs for the treatment of CNS disorders. The company uses a proprietary chemical technology platform that enables the identification and optimization of novel compounds. An important component of ACADIA Pharmaceuticals' business model is its focus on partnerships with other companies and institutions. By collaborating with other pharmaceutical companies, ACADIA Pharmaceuticals can access a wider network of resources and expertise to accelerate the development of new medications and reduce costs. The company also works closely with academic research institutions to advance the research and development of new compounds. In 2020, ACADIA Pharmaceuticals generated approximately $1.1 billion in revenue. The company employs approximately 1,500 people worldwide and has marketed its products in over 20 countries. ACADIA Pharmaceuticals is listed on the NASDAQ stock exchange under the symbol ACAD. In summary, ACADIA Pharmaceuticals' business model is based on the development and commercialization of innovative therapies for CNS disorders. The company utilizes a proprietary technology platform and collaborates closely with other companies and research institutions to accelerate the development of new medications. With a successful market entry of Nuplazid in 2020, ACADIA Pharmaceuticals is on track to achieve its goals and further expand its business model.

What is the ACADIA Pharmaceuticals dividend?

ACADIA Pharmaceuticals pays a dividend of 0 USD distributed over payouts per year.

How often does ACADIA Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for ACADIA Pharmaceuticals or the company does not pay out a dividend.

What is the ACADIA Pharmaceuticals ISIN?

The ISIN of ACADIA Pharmaceuticals is US0042251084.

What is the ACADIA Pharmaceuticals WKN?

The WKN of ACADIA Pharmaceuticals is 603035.

What is the ACADIA Pharmaceuticals ticker?

The ticker of ACADIA Pharmaceuticals is ACAD.

How much dividend does ACADIA Pharmaceuticals pay?

Over the past 12 months, ACADIA Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ACADIA Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of ACADIA Pharmaceuticals?

The current dividend yield of ACADIA Pharmaceuticals is .

When does ACADIA Pharmaceuticals pay dividends?

ACADIA Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of ACADIA Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is ACADIA Pharmaceuticals located?

ACADIA Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von ACADIA Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of ACADIA Pharmaceuticals from 9/9/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/9/2024.

When did ACADIA Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/9/2024.

What was the dividend of ACADIA Pharmaceuticals in the year 2023?

In the year 2023, ACADIA Pharmaceuticals distributed 0 USD as dividends.

In which currency does ACADIA Pharmaceuticals pay out the dividend?

The dividends of ACADIA Pharmaceuticals are distributed in USD.

All fundamentals about ACADIA Pharmaceuticals

Our stock analysis for ACADIA Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ACADIA Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.